Gadolinium neutron capture therapy (GdNCT) of melanoma cells and solid tumors with the magnetic resonance imaging contrast agent gadobutrol

Investigative Radiology

Volumn 34, Issue 2, 1999, Pages 126-133

  Hofmann, Birte ^a   Fischer, Carl Otto ^b   Lawaczeck, Rüdiger ^a,d   Platzek, Johannes ^c   Semmler, Wolfhard ^a  

^a Research Laboratories   (Germany)

^b HAHN MEITNER INSTITUT   (Germany)

^c BAYER PHARMA AG   (Germany)

^d Inst fur Diagnostikforschung GmbH   (Germany)

Author keywords

Gadolinium; Melanoma cells; MRI contrast agent; Neutron capture therapy for cancer; Solid tumor

Indexed keywords

CONTRAST MEDIUM; GADOBUTROL; GADOLINIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; FEMALE; INTRATUMORAL DRUG ADMINISTRATION; MELANOMA; MOUSE; NEUTRON CAPTURE THERAPY; NEUTRON RADIATION; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR;

EID: 0033027441     PISSN: 00209996     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004424-199902000-00005     Document Type: Article

References (24)

1. Barth RF, Soloway AH, Fairchild R G. Boron neutron therapy for cancer. Sci Am 1990;263:100-107.
2. Sauerwein W. Principles and history of neutron capture therapy Strahlenther Onkol 1992;169:1-6.
3. 157Gd neutron capture. Pigment Cell Res 1989;2:330-332.
4. Shih JLA, Brugger RM. Gadolinium as a neutron capture therapy agent. Med Phys 1992;19:733-744.
5. Brugger RM, Shih JLA. Evaluation of gadolinium-157 as a neutron capture therapy agent. Strahlenther Onkol 1989;165:153-156.
6. Hatanaka H. New dimensions of boron thermal neutron capture therapy in neurosurgery. In: Soloway AH, Barth RF, Carpenter DE, eds. Advances in neutron capture therapy. New York: Plenum, 1993;665-669.
7. 10B molecule-melanoma cell interaction from in vitro to first clinical trials. Pigment Cell Res 1989;2:226-234.
8. Flam F. Boron therapy gets early test. Science 1994;265:1799.
9. Lawler A. Brookhaven prepares for boron trials. Science 1995;267: 956.
10. Elowitz EH, Chadha M, Iwai J, et al. A phase I/II trial of boron neutron capture therapy (BNCT) for glioblastoma multiforme using intravenous boronophenyalanine-fructose complex and epithermal neutrons: Early clinical results. In: Larsson B, Crawford J, Weinreich R, eds. Advances in neutron capture therapy. Amsterdam: Elsevier, 1997;56-59.
11. Busse P, Zamenhof R, Madoc-Jones H, et al. Clinical follow-up of patients with melanoma of the extremity treated in a phase I boron neutron capture therapy protocol. In: Larsson B, Crawford J, Weinreich R, eds. Advances in neutron capture therapy. Amsterdam: Elsevier. 1997;60-64.
12. 11SH (BSH) in patient with malignant glioma as precondition for boron neutron capture therapy. Int J Radiat Oncol Biol Phys 1994;28:1175-1181.
13. Schoerner W, Felix R, Laniado M, et al. Pruefung des kernspintomographischen Kontrastmittels Gadolinium-DTPA am Menschen. Fortschr Röentgenstr 1984;140:493-500.
14. Akine Y, Tokita N, Matsumoto T, Oyama H, Egawa S, Aizawa O. Radiation effects of gadolinium-neutron capture reactions on the survival of Chinese hamster cells. Strahlenther Onkol 1990;166:831-833.
15. Akine Y, Tokita N, Tokuuye K, et al. Suppression of rabbit VX-2 subcutaneous tumor growth by gadolinium neutron capture therapy. Jpn J Cancer Res 1993;84:841-843.
16. Akine Y, Tokita N, Tukuuye K, et al. Neutron capture therapy of murine-ascites tumor with Gd-containing microcapsules. J Cancer Res Clin Oncol 1992;119:71-73.
17. Akine Y, Tokita N, Tokuuye K, Satoh M, Kobayashi T, Kanda K. Electron-equivalent dose for the effect of gadolinium neutron capture therapy on the growth of subcutaneously-inoculated Ehrlich tumor cells in mice. Jpn J Clin Oncol 1993;23:145-148.
18. Hartmann M, Forsting M, Jansen O, Albert FK, Balzer T, Sartor K. Verbessert die Hochdosisgabe eines paramagnetischen Kontrastmittels (Gadovist®) die diagnostische Aussage der Magnetresonanztomographie bei Glioblastomen? Fortschr Röntgenstr 1996;164, 2:119-125.
19. Vogler H, Platzek J, Schuhmann-Giampieri G, et al. Pre-clinical evaluation of gadobutrol: A new neutral extracellular contrast agent for magnetic resonance imaging. Eur J Radiol 1996;21:1-10.
20. Carey TE, Takahashi T, Resnick LA, Oettgen HF, Old LJ. Cell surface antigens of human malignant melanoma: Mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells. Proc Natl Acad Sci USA 1976;73:3278-3282.
21. Lawaczeck R, Fischer CO, Krueger U, Leuther W, Menrad J. Gadolinium neutron capture (GdNCT) with MRI contrast media: In vitro studies. In: Mishima Y, ed. Cancer neutron capture therapy. New York: Plenum Press, 1996;859-864.
22. Berger B, Fischer CO, Lawaczeck R, Platzek J, Schwartz-Porsche D, Semmler W. Neutron capture therapy (NCT) with a macrocyclic Gd-complex. In: Larsson B, Crawford J, Weinreich R, eds. Advances in neutron capture therapy. Amsterdam: Elsevier, 1997; 440-446.
23. Barth RF, Soloway AH, Brugger RM. Boron neutron capture therapy of brain tumors: Past history, current status, and future potential. Cancer Invest 1996;14:534-550.
24. Khokhlov VF, Yashkin PN, Silin DI, Djorova ES, Lawaczeck R. Neutron capture therapy with gadopentetate dimeglumine: Experiments on tumor-bearing rats. Acad Radiol 1995;2:392-398.